HemoChat is an evidence-based AI medical search tool covering all major clinical domains, powered by 46,298 SNOMED-CT concepts, clinical guidelines, and live PubMed literature.

What medical domains does HemoChat cover?

HemoChat covers all major medical domains including cardiology, oncology, neurology, hematology, pulmonology, endocrinology, gastroenterology, psychiatry, nephrology, rheumatology, musculoskeletal, and more — with 46,298 SNOMED-CT concepts.

Is HemoChat a replacement for clinical judgment?

No. HemoChat is for clinical reference only and is not a substitute for professional medical judgment. Always consult qualified healthcare professionals for medical decisions.

What AI technology does HemoChat use?

HemoChat uses a hybrid GraphRAG + VectorRAG pipeline combining Neo4j knowledge graphs with FAISS vector search and an LLM for answer generation.

Muscle eye brain disease — Clinical Guidelines

Overview

Muscle Eye Brain Disease (MEB) is a rare, autosomal recessive neurodegenerative disorder characterized by progressive muscle weakness, ocular abnormalities, and brain malformations, primarily affecting the cerebellum and brainstem 1.

Diagnosis

Clinical Presentation: Progressive muscle weakness, ophthalmological abnormalities (e.g., nystagmus, strabismus), and characteristic brain malformations on imaging 1.

Genetic Testing: Identification of mutations in the KIF11 gene or related pathways 1.

Neuroimaging: MRI showing characteristic cerebellar and brainstem abnormalities 1.

Muscle Biopsy: May reveal nonspecific myopathic changes; histopathology not specific but can support clinical suspicion 4.

Management

Supportive Care: Physical therapy to maintain muscle function, ophthalmological interventions for visual impairments 1.

Symptomatic Treatment: Addressing specific symptoms such as seizures with anticonvulsants, respiratory issues with ventilatory support 1.

Genetic Counseling: Essential for families due to the genetic nature of the disease 1.

Special Populations

Pediatrics: Early diagnosis and intervention are crucial for managing developmental delays and motor impairments 1.

Comorbidities: Management of associated conditions like respiratory complications requires multidisciplinary care 1.

Key Recommendations

Genetic Testing for Diagnosis: Confirm diagnosis through genetic analysis of KIF11 mutations 1 (Evidence: Strong).

Multidisciplinary Approach: Implement a comprehensive care plan involving neurology, ophthalmology, and physical therapy 1 (Evidence: Moderate).

Early Intervention: Initiate supportive therapies early to mitigate developmental and motor impairments in pediatric patients 1 (Evidence: Moderate).

References

1 Kraft S. What Did They Know Then? A Journey Among the Giants of the Past. Journal of binocular vision and ocular motility 2018. link 2 Walters RJ. Contractures and muscle disease. Practical neurology 2016. link 3 Hedenmalm K, Granberg AG, Dahl ML. Statin-induced muscle toxicity and susceptibility to malignant hyperthermia and other muscle diseases: a population-based case-control study including 1st and 2nd degree relatives. European journal of clinical pharmacology 2015. link 4 Harris BT, Mohila CA. Essential muscle pathology for the rheumatologist. Rheumatic diseases clinics of North America 2011. link 5 Vlychou M, Teh J. Ultrasound of muscle. Current problems in diagnostic radiology 2008. link 6 Mirken B. "Mental" issue threatens medical care. AIDS treatment news 2000. link 7 Damiani E, Salvatori S, Zorzato F, Margreth A. Characteristics of skeletal muscle calsequestrin: comparison of mammalian, amphibian and avian muscles. Journal of muscle research and cell motility 1986. link 8 Jennissen HP, Petersen-Von Gehr JK, Botzet G. Activation and inhibition of phosphorylase kinase by monospecific antibodies against preparatively isolated alpha, beta and gamma subunits. European journal of biochemistry 1985. link 9 Dahl D, Rueger DC, Crosby CJ, Bignami A. Cell-specific domains of glial- and muscle-type intermediate filament proteins. Immunoaffinity chromatography and immunoblotting study of GFA protein and desmin. Experimental cell research 1984. link90170-8) 10 Ibi T, Sahashi K, Kato K, Takahashi A, Sobue I. Immunohistochemical demonstration of beta-enolase in human skeletal muscle. Muscle & nerve 1983. link 11 Stauber WT, Fritz V, Dahlmann B, Reinauer H. Immunohistochemical localization of two proteinases in skeletal muscle. The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society 1983. link 12 Shulman S, Milgrom F, Swanborg RH. Immunochemical studies of an organ-specific thermostable antigen of bovine brain. Immunology 1969. link

Muscle eye brain disease